Drug Search Results
More Filters [+]

Goserelin

Alternative Names: goserelin, zoladex
Latest Update: 2024-11-12
Latest Update Note: Clinical Trial Update

Product Description

Goserelin is a type of hormone therapy called luteinising hormone blocker. This means it stops the release of luteinising hormone (LH) from the pituitary gland. Goserelin is a treatment for people who have oestrogen receptor positive (ER positive) breast cancer. This means that the cancer has proteins (receptors) for the hormone oestrogen. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/goserelin-breast-cancer)

Mechanisms of Action: GnRH Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Endometriosis | Breast Cancer | Endometrial Cancer | Prostate Cancer | Uterine Cancer | Oncology Unspecified | Injuries/wounds Unspecified

Known Adverse Events: Depressive Disorder | Headache | Breast Cancer | Uterine Cancer | Oncology Unspecified | Vaginitis | Edema | Hot Flashes | Lower Urinary Tract Symptoms | Injuries/wounds Unspecified

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Goserelin

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Italy, Japan, Jordan, Korea, Lebanon, Malaysia, Mexico, Netherlands, Poland, Portugal, Russia, Saudi Arabia, Singapore, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 24

Highest Development Phases

Phase 3: Adenocarcinoma|Bone Cancer|Breast Cancer|Endometriosis|Male Breast Cancer|Prostate Cancer

Phase 2: Lobular Carcinoma|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PREDICT-RT*

P3

Recruiting

Prostate Cancer|Bone Cancer|Adenocarcinoma

2033-12-31

S65935

P3

Unknown Status

Prostate Cancer

2032-06-01

GUIDANCE

P3

Recruiting

Prostate Cancer|Adenocarcinoma

2032-04-30

ESCALATE

P2

Not yet recruiting

Triple Negative Breast Cancer

2026-12-01

Recent News Events